Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for managing near vision loss.
|Poll|October 22, 2021
Poll: What pipeline presbyopia treatment are you most looking forward to?
Author(s)Brooke Henson, Editor
This poll is for optometrists and eyecare professionals, only. It will close on Friday, November 5, 2021.
Advertisement
What pipeline presbyopia treatment are you most looking forward to?
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
More than monitoring: Using AMD visits to promote healthy vision aging
2
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
3
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
4
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5